The impact of Susan G. Komen-funded research on approved drugs for breast cancer treatment.

Introduction: Susan G. Komen® (Komen) has invested nearly $1.1 billion in ground-breaking breast cancer research since 1982. As a patient-centered organization, Komen measures research funding impact beyond academic metrics in favor of economic value and societal effects. Here, we highlight an innovative approach to assessing the real-world impact of Komen-funded research by showing how Komen funding for pivotal studies and key personnel conducting research contributed to discovery and development of targeted therapy drugs approved to treat breast cancer by the United States Food and Drug Administration (FDA) between 2012 and 2023. Methods: We utilized bibliometric analysis to work backwards through citations within pivotal Phase III clinical trial publications to identify earlier clinical trials, pre-clinical research, and basic research publications that supported development of each drug, evaluating each published study and contributing authors for Komen funding support. Results: All 19 targeted therapy drugs approved by the FDA between 2012 and 2023 were impacted at multiple phases along the drug development pipeline by Komen funding, including direct impacts in basic research (i.e., investments in projects) that supported target discovery, and impacts in support of key personnel who contributed to pivotal studies and clinical trials (i.e., investments in people) that led to approval. Conclusions: Nonprofit and public sector research funding provide the foundation for the drug development pipeline. This paper highlights an innovative approach to assess the impact of research investments beyond traditional academic measures and underscores the significance of nonprofit, patient-centered organizations like Komen in driving drug development through supporting basic and applied research.